Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms.


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
11 2021
Historique:
received: 22 03 2021
accepted: 25 10 2021
entrez: 16 11 2021
pubmed: 17 11 2021
medline: 31 12 2021
Statut: ppublish

Résumé

A potential role for the orphan G protein-coupled receptor, GPR21, in linking immune cell infiltration into tissues and obesity-induced insulin resistance has been proposed, although limited studies in mice are complicated by non-selective deletion of We hypothesized that a High-fat feeding studies in Collectively, human and mouse data suggest that GPR21 influences both glucose homeostasis and MCP-1/CCL2-CCR2-driven monocyte migration. However, a

Identifiants

pubmed: 34782333
pii: 9/2/e002285
doi: 10.1136/bmjdrc-2021-002285
pmc: PMC8593704
pii:
doi:

Substances chimiques

CCL2 protein, human 0
CCR2 protein, human 0
Ccr2 protein, mouse 0
Chemokine CCL2 0
GPR21 protein, human 0
GPR21 protein, mouse 0
Receptors, CCR2 0
Receptors, G-Protein-Coupled 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cell Metab. 2015 Mar 3;21(3):403-16
pubmed: 25738456
Genet Mol Biol. 2018 Jan-Mar;41(1):167-179
pubmed: 29583154
BMC Bioinformatics. 2014 Jun 12;15:182
pubmed: 24925680
J Clin Invest. 2012 Jul;122(7):2444-53
pubmed: 22653059
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31589290
Pharmacol Rev. 2016 Oct;68(4):954-1013
pubmed: 27630114
Biomolecules. 2015 Jul 21;5(3):1563-79
pubmed: 26197341
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Med. 2016 Jul;22(7):780-91
pubmed: 27270589
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Rev Immunol. 2011 Feb;11(2):98-107
pubmed: 21233852
Cell Growth Differ. 1991 Jun;2(6):267-72
pubmed: 1712226
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
J Clin Endocrinol Metab. 2014 Jul;99(7):2500-9
pubmed: 24606068
Bioinformatics. 2007 Dec 1;23(23):3251-3
pubmed: 17644558
Kidney Int Rep. 2018 Aug 03;3(6):1316-1327
pubmed: 30450458
Cell Metab. 2018 Jul 03;28(1):175-182.e5
pubmed: 29861387
Expert Opin Investig Drugs. 2015 Mar;24(3):283-307
pubmed: 25345753
J Leukoc Biol. 2006 Dec;80(6):1542-52
pubmed: 16940330
F1000Res. 2016 Feb 04;5:136
pubmed: 27081476
Circulation. 2012 Dec 4;126(23):2739-48
pubmed: 23129601
Semin Immunol. 2012 Dec;24(6):436-42
pubmed: 23333525
EMBO J. 2006 Jan 25;25(2):278-89
pubmed: 16395330
Nat Rev Immunol. 2004 Feb;4(2):110-22
pubmed: 15040584
PLoS One. 2017 Apr 26;12(4):e0175524
pubmed: 28445487
Eur Cardiol. 2019 Apr;14(1):50-59
pubmed: 31131037
Cardiovasc Res. 2015 Aug 1;107(3):321-30
pubmed: 25990461
Cell. 2008 Oct 31;135(3):561-71
pubmed: 18984166
PLoS One. 2018 May 10;13(5):e0197177
pubmed: 29746559
Front Immunol. 2014 Nov 21;5:554
pubmed: 25484881
Pharmacol Rev. 2018 Jan;70(1):39-67
pubmed: 29233848
Annu Rev Physiol. 2010;72:219-46
pubmed: 20148674
Endocrine. 2017 Feb;55(2):360-365
pubmed: 27230767
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
EMBO J. 1999 Apr 1;18(7):1772-82
pubmed: 10202141
Biomark Res. 2014 Jan 07;2(1):1
pubmed: 24398220
Biochem Biophys Res Commun. 2012 Feb 3;418(1):1-5
pubmed: 22155242
Obesity (Silver Spring). 2007 Jun;15(6):1419-29
pubmed: 17557979
Theriogenology. 2019 Jul 1;132:1-11
pubmed: 30981084
J Am Coll Cardiol. 2018 May 29;71(21):2392-2401
pubmed: 29544870
J Clin Invest. 2006 Jan;116(1):115-24
pubmed: 16341265
Nat Rev Immunol. 2011 Oct 10;11(11):738-49
pubmed: 21984069

Auteurs

Darren M Riddy (DM)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia darren.riddy@monash.edu chris.langmead@monash.edu.

Helene L Kammoun (HL)

Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Andrew J Murphy (AJ)

Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Sanja Bosnyak-Gladovic (S)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Rocio De la Fuente Gonzalez (R)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Jon Merlin (J)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Mark Ziemann (M)

Department of Diabetes, Monash University Central Clinical School, Melbourne, Victoria, Australia.

Stewart Fabb (S)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Tracie L Pierce (TL)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Natalie Diepenhorst (N)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Patricia Rueda (P)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Assam El-Osta (A)

Department of Diabetes, Monash University Central Clinical School, Melbourne, Victoria, Australia.

Jean-Francois Gautier (JF)

Inserm UMRS 1138, Département Diabète et Endocrinologie, Sorbonne Université, Paris, France.

Nicolas Venteclef (N)

Inserm UMRS 1138, Département Diabète et Endocrinologie, Sorbonne Université, Paris, France.

William N Charman (WN)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Arthur Christopoulos (A)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Patrick M Sexton (PM)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Roger J Summers (RJ)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Mark A Febbraio (MA)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.

Philippe Delerive (P)

Pôle d'Innovation Thérapeutique Métabolisme, Institut de Recherches Internationales Servier, Suresnes, France.

Christopher J Langmead (CJ)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia darren.riddy@monash.edu chris.langmead@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH